Jim Saulnier & Associates LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Jim Saulnier & Associates LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 237 shares of the company’s stock, valued at approximately $210,000.

Several other large investors also recently modified their holdings of the stock. KKM Financial LLC raised its position in shares of Eli Lilly and Company by 8.2% in the third quarter. KKM Financial LLC now owns 2,941 shares of the company’s stock valued at $2,606,000 after purchasing an additional 222 shares during the period. Algert Global LLC increased its position in Eli Lilly and Company by 2,059.9% during the third quarter. Algert Global LLC now owns 10,886 shares of the company’s stock worth $9,644,000 after acquiring an additional 10,382 shares during the period. Kingsview Wealth Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter. Kingsview Wealth Management LLC now owns 54,679 shares of the company’s stock worth $48,442,000 after acquiring an additional 1,849 shares during the period. Cerity Partners LLC increased its position in Eli Lilly and Company by 9.4% during the third quarter. Cerity Partners LLC now owns 580,520 shares of the company’s stock worth $512,568,000 after acquiring an additional 50,091 shares during the period. Finally, Optivise Advisory Services LLC bought a new position in Eli Lilly and Company during the third quarter worth about $1,731,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $748.01 on Friday. The company has a fifty day moving average of $865.01 and a 200-day moving average of $869.65. The firm has a market capitalization of $710.10 billion, a P/E ratio of 80.87, a P/E/G ratio of 2.84 and a beta of 0.43. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analysts Set New Price Targets

A number of research firms recently commented on LLY. Bank of America lowered their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.